An interview with:
Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France
PARIS, France—A clinical trial using a personalized therapeutic vaccine, that recognizes multiple genetic features of each patient’s tumor, brought durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancers, and also prevented relapse in some patients.
At the 2024 Annual Meeting of the American Association for Cancer Research, held in San Diego, California, Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory at the Institut Curie in Paris, gave the Audio Journal of Oncology the latest update on his findings with the “neoantigen vaccine”.
AACR 2024 Abstract Number: LB401
ABSTRACT TITLE: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
